PDSB · PDS Biotechnology Corp
$0.75
+0.04 (+6.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$44.61M
Shares
55.97M
Volume · Oct 2
3.66M
Avg daily vol (3M)
21.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.75
Open$0.72
Day$0.71–0.75
52W close$0.20–1.43
Avg vol 30d44.2M
Short int6.4M · 11.4% float · 1.0d
Short vol46%
Last earningsMay 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
call held May 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-26.6%
Trailing year
Short interest
11.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
+47%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
45%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+240%
trailing
6-month return
−31%
trailing
YTD return
−3%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.45% of float · ▲ +172.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
+28%
Y/Y
Free cash flow
$-27.8M
Balance sheet
$124.7M
net cash
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
13.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed May 13, 2020
Burn
· going forward
$3M – $4M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
+47%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
45%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.45% of float · ▲ +172.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 45%
Range high $1
vs 200-day avg -6%
vs 50-day avg +47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PDSB
this stock
PDS Biotechnology Corp
|
$44.61M | -2.8% | — | — | 11.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PDSB | -6.1% | +240.2% | -31.3% | -0.3% | -2.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.9% | +240.7% | -43.5% | -1.2% | -15.7% |